Literature DB >> 21160066

Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.

Tong Ying Shun1, John S Lazo, Elizabeth R Sharlow, Paul A Johnston.   

Abstract

High-throughput screening (HTS) has achieved a dominant role in drug discovery over the past 2 decades. The goal of HTS is to identify active compounds (hits) by screening large numbers of diverse chemical compounds against selected targets and/or cellular phenotypes. The HTS process consists of multiple automated steps involving compound handling, liquid transfers, and assay signal capture, all of which unavoidably contribute to systematic variation in the screening data. The challenge is to distinguish biologically active compounds from assay variability. Traditional plate controls-based and non-controls-based statistical methods have been widely used for HTS data processing and active identification by both the pharmaceutical industry and academic sectors. More recently, improved robust statistical methods have been introduced, reducing the impact of systematic row/column effects in HTS data. To apply such robust methods effectively and properly, we need to understand their necessity and functionality. Data from 6 HTS case histories are presented to illustrate that robust statistical methods may sometimes be misleading and can result in more, rather than less, false positives or false negatives. In practice, no single method is the best hit detection method for every HTS data set. However, to aid the selection of the most appropriate HTS data-processing and active identification methods, the authors developed a 3-step statistical decision methodology. Step 1 is to determine the most appropriate HTS data-processing method and establish criteria for quality control review and active identification from 3-day assay signal window and DMSO validation tests. Step 2 is to perform a multilevel statistical and graphical review of the screening data to exclude data that fall outside the quality control criteria. Step 3 is to apply the established active criterion to the quality-assured data to identify the active compounds.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21160066     DOI: 10.1177/1087057110389039

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  19 in total

1.  High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.

Authors:  Paul A Johnston; Malabika Sen; Yun Hua; Daniel Camarco; Tong Ying Shun; John S Lazo; Jennifer R Grandis
Journal:  Assay Drug Dev Technol       Date:  2013-10-15       Impact factor: 1.738

2.  Development and validation of a cell-based assay system to assess human immunodeficiency virus type 1 integrase multimerization.

Authors:  Tomofumi Nakamura; Joseph R Campbell; Amber R Moore; Sachiko Otsu; Haruo Aikawa; Hirokazu Tamamura; Hiroaki Mitsuya
Journal:  J Virol Methods       Date:  2016-07-26       Impact factor: 2.014

3.  High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.

Authors:  Yun Hua; Tong Ying Shun; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2014-09       Impact factor: 1.738

4.  Development and validation of a high-content bimolecular fluorescence complementation assay for small-molecule inhibitors of HIV-1 Nef dimerization.

Authors:  Jerrod A Poe; Laura Vollmer; Andreas Vogt; Thomas E Smithgall
Journal:  J Biomol Screen       Date:  2013-11-26

5.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

6.  Challenges in secondary analysis of high throughput screening data.

Authors:  Aurora S Blucher; Shannon K McWeeney
Journal:  Pac Symp Biocomput       Date:  2014

Review 7.  Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis.

Authors:  Tian Zhu; Shuyi Cao; Pin-Chih Su; Ram Patel; Darshan Shah; Heta B Chokshi; Richard Szukala; Michael E Johnson; Kirk E Hevener
Journal:  J Med Chem       Date:  2013-06-07       Impact factor: 7.446

8.  Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.

Authors:  Paul A Johnston; Minh M Nguyen; Javid A Dar; Junkui Ai; Yujuan Wang; Khalid Z Masoodi; Tongying Shun; Sunita Shinde; Daniel P Camarco; Yun Hua; Donna M Huryn; Gabriela Mustata Wilson; John S Lazo; Joel B Nelson; Peter Wipf; Zhou Wang
Journal:  Assay Drug Dev Technol       Date:  2016-05       Impact factor: 1.738

9.  Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus.

Authors:  Paul A Johnston; Sunita N Shinde; Yun Hua; Tong Ying Shun; John S Lazo; Billy W Day
Journal:  Assay Drug Dev Technol       Date:  2012-07-25       Impact factor: 1.738

10.  Identification of 3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine Derivatives as Novel Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase.

Authors:  Endah Dwi Hartuti; Takaya Sakura; Mohammed S O Tagod; Eri Yoshida; Xinying Wang; Kota Mochizuki; Rajib Acharjee; Yuichi Matsuo; Fuyuki Tokumasu; Mihoko Mori; Danang Waluyo; Kazuro Shiomi; Tomoyoshi Nozaki; Shinjiro Hamano; Tomoo Shiba; Kiyoshi Kita; Daniel Ken Inaoka
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.